A patient with HIV disease is on Highly Active Anti Retroviral Therapy (HAART). He develops tuberculosis. Which one of the following anti-tubercular drugs interferes with HAART?
## **Core Concept**
The question tests the interaction between anti-tubercular drugs and Highly Active Anti Retroviral Therapy (HAART) in a patient with HIV disease. HAART, also known as Antiretroviral Therapy (ART), is crucial for managing HIV, and its effectiveness can be influenced by other medications due to drug interactions.
## **Why the Correct Answer is Right**
Rifampicin (**) is a potent inducer of the cytochrome P450 enzyme system, particularly the CYP3A4 isoenzyme. This induction leads to increased metabolism of many drugs, including those used in HAART, such as protease inhibitors and non-nucleoside reverse transcriptase inhibitors (NNRTIs). As a result, the plasma concentrations of these HAART drugs can decrease, potentially leading to reduced efficacy and the development of resistance. Therefore, when a patient on HAART develops tuberculosis and requires treatment with rifampicin, careful consideration and adjustment of the HAART regimen are necessary to avoid these interactions.
## **Why Each Wrong Option is Incorrect**
- **Option A:** Isoniazid (**) is primarily metabolized by the liver and can cause hepatotoxicity but does not significantly induce the cytochrome P450 system to the extent that it interferes with HAART in the same way rifampicin does. It can have some drug interactions but is not the primary concern with HAART.
- **Option B:** Ethambutol (**), while it can cause optic neuritis as a side effect, does not significantly interact with the cytochrome P450 system or interfere with HAART.
- **Option C:** Pyrazinamide (**) can cause hepatotoxicity but does not have significant interactions with the HAART regimen through the cytochrome P450 system.
## **Clinical Pearl / High-Yield Fact**
A key clinical consideration in patients with HIV on HAART who develop tuberculosis is the management of drug interactions, particularly with rifampicin. A strategy to manage these interactions includes using rifabutin (**), which is a less potent inducer of CYP3A4, or adjusting the HAART regimen to maintain therapeutic drug levels. Always consult current guidelines and consider consulting a pharmacist or specialist for managing complex drug interactions.
## **Correct Answer:** . Rifampicin